Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03595306 · ClinicalTrials.gov registry record · NA
Human Gut Microbiota and Prebiotic Response
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT03595306: Completed NA study, sponsored by Duke University.
NCT03595306 is a NA study that has completed, run by Duke University. The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03595306, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
This study is designed to examine the shift in gut microbiota and their metabolism after consumption of a dietary supplement (prebiotic) by healthy participants. The investigators will provide participants with a panel of over the counter prebiotics and monitor their gut microbiome response in stool. All prebiotics will be commercially available, over-the-counter food, food additives, or dietary supplements, without any known market-use adverse effects beyond minimal discomfort.
Interventions
- DIETARY_SUPPLEMENT Prebiotic A - inulin
- DIETARY_SUPPLEMENT Prebiotic B - galactooligosaccharides(GOS)
- DIETARY_SUPPLEMENT Prebiotic C - wheat dextrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2019-05-19 |
| Phase | NA |
What the finished NCT03595306 record still lists
NCT03595306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Prebiotic A - inulin is the first listed.
NCT03595306 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03595306 about?
NCT03595306 is a clinical study titled "Human Gut Microbiota and Prebiotic Response". This study is designed to examine the shift in gut microbiota and their metabolism after consumption of a dietary supplement (prebiotic) by healthy participants. The investigators will provide participants with a panel of over the counter prebiotics and monitor their gut microbiome response in stool...
What is the current status of trial NCT03595306?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. The study started on 2018-05-01. Estimated completion is 2019-05-19.
What interventions are being tested in trial NCT03595306?
The interventions under investigation include: Prebiotic A - inulin (DIETARY_SUPPLEMENT), Prebiotic B - galactooligosaccharides(GOS) (DIETARY_SUPPLEMENT), Prebiotic C - wheat dextrin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03595306?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03595306's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI